Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 14/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.37 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2876719 | 0.82 | ALOX15 (0.40) | SIRT1SIRT2SIRT3LMNATP53 | |
| SCHEMBL4319804 | 0.81 | MAP2 (0.48) | SIRT1SIRT2SIRT3ALOX15SMN1; SMN2 | |
| SCHEMBL4319380 | 0.78 | MAP2 (0.47) | SIRT1SIRT2SIRT3ALOX15SMN1; SMN2 | |
| SCHEMBL4313647 | 0.77 | ALDH1A1 (0.53) | LMNATP53ALOX15SMN1; SMN2MEN1 | |
| SCHEMBL4317335 | 0.76 | MAP2 (0.50) | SIRT1SIRT2SIRT3 | |
| SCHEMBL4310041 | 0.74 | ALDH1A1 (0.52) | LMNAALOX15SMN1; SMN2MEN1MAPT | |
| SCHEMBL2882093 | 0.74 | OPRM1 (0.36) | LMNATP53ALOX15SMN1; SMN2OPRM1 | |
| SCHEMBL4317805 | 0.72 | ALDH1A1 (0.54) | LMNATP53ALOX15SMN1; SMN2MEN1 | |
| SCHEMBL14194790 | 0.71 | SIRT1 (0.45) | SIRT1SIRT2LMNAMEN1MAPT | |
| SCHEMBL5729606 | 0.67 | SIRT1 (0.46) | SIRT1SIRT2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168097-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | MERCK SHARP & DOHME CORP. | 2010-07-01 | — | — | US | disclosed |
| EP-1898928-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007002458-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168097-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | RNGTT, POLR1E, RTF1 | SIRT1 1501/4885SIRT2 2009/4885SIRT3 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.